Regístrese ahora para una mejor cotización personalizada!
A medicine designed by using artificial intelligence (AI) is about to enter clinical human trials for the first time. Developed by British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma, the medicine will be used to treat patients with obsessive-compulsive disorder. Its creation spanned 12 months, significantly less than a usual medicine developing process which takes about five years. The process involved algorithms that shifted through potential compounds checking them against a huge database of parameters. The medicine will first enter clinical trials in Japan.
Etiquetas calientes:
Inteligencia Artificial
Regístrepor correo electrónico ahora para acciones semanales de promoción
100% free, Unsubscribe any time!
Add 1: Room 605 6/F FA YUEN Commercial Building, 75-77 FA YUEN Street, Mongkok KL, HongKong Add 2: Room 405, Building E, MeiDu Building, Gong Shu District, Hangzhou City, Zhejiang Province, China
Whatsapp/Tel: +8618057156223 Tel: 0086 571 86729517 Tel en Hong Kong: 00852 66181601
Correo electrónico: [email protected]
English
Pусский
Français
Español
Português
